5-(4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 5-(4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione
• 英文别名: (5Z)-5-[[4-[4-[1,3-benzoxazol-2-yl(methyl)amino]butoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₂H₂₁N₃O₄S
• 分子量: 423.492
• InChiKey: JAOURTOEKIOJCW-RGEXLXHISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-(4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione 生成 5-(4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]-benzyl)-2,4-thiazolidinedione
  参考文献：
  名称：

  Compounds

  摘要：

  式(I)的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化合物，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基基团，酰基基团，芳基烷基基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共最多具有五个取代基的苯环；n代表范围为2至6的整数；含有这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。

  公开号：

  US05232925A1
• 作为产物：
  描述：

  2-氯苯并恶唑 在 吡啶 、 哌啶乙酸盐 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 26.0h， 生成 5-(4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione
  参考文献：
  名称：

  [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

  摘要：

  A series of [(ureidoethoxy)benzyl]-2,4-thiazolidinediones and [[(heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones was synthesized from the corresponding aldehydes. Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045). The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies. Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 Bl/6 ob/ob mice. From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.

  DOI：

  10.1021/jm00049a017

文献信息

• Compounds
  申请人：Beecham Group p.l.c.

  公开号：US05232925A1

  公开（公告）日：1993-08-03

  Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  式(I)的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化合物，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基基团，酰基基团，芳基烷基基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共最多具有五个取代基的苯环；n代表范围为2至6的整数；含有这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。
• NOVEL COMPOUNDS
  申请人：Beecham Group p.1.c.

  公开号：US20020049240A1

  公开（公告）日：2002-04-25

  Compounds of formula (I): 1 or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A 1 represents a substituted or unsubstituted aromatic heterocyclyl group; R 1 represents a hydrocarbon atom, an alkyl group, an acyl grup, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R 2 and R 3 each represent hydrogen, or R 2 and R 3 together represent a bond; A 2 represents a benzene ring having a total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  化合物的式子（I）：其中1或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂盐，其中：A1代表取代或未取代的芳香杂环基团；R1代表碳氢原子，烷基，酰基，苯基烷基，其中芳基部分可能被取代或未取代，或者是取代或未取代的芳基基团；R2和R3分别代表氢，或者R2和R3一起代表一个键；A2代表苯环，具有最多五个取代基；n代表在2到6之间的整数；包含这种化合物的药物组合物以及这种化合物和组合物在医学上的用途。
• Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs10524523
  申请人：Zinfandel Pharmaceuticals, Inc.

  公开号：EP2789695A1

  公开（公告）日：2014-10-15

  Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided..

  本文提供了一种用于鉴定与相关疾病（如阿尔茨海默病）发展相关的基因变异体的方法，以及所鉴定的基因变异体。还提供了在检测到本文所述基因变异体后使用活性制剂（如使用特定活性制剂和/或在较早年龄使用）进行治疗的方法。在某些实施方案中，基因变异是 TOMM40 基因的缺失/插入多态性（DIP）。还提供了用于确定受试者患晚期阿尔茨海默病的风险是否增加的试剂盒。还提供了用于确定受试者是否对活性制剂治疗相关疾病有反应的试剂盒。
• Method of identifying disease risk factors
  申请人：Zinfandel Pharmaceuticals, Inc.

  公开号：US10865449B2

  公开（公告）日：2020-12-15

  Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.

  本文提供了一种用于鉴定与相关疾病（如阿尔茨海默病）发展相关的基因变异体的方法，以及所鉴定的基因变异体。还提供了在检测到本文所述基因变异体后使用活性制剂（如使用特定活性制剂和/或在较早年龄使用）进行治疗的方法。在某些实施方案中，基因变异是 TOMM40 基因的缺失/插入多态性（DIP）。还提供了用于确定受试者患晚期阿尔茨海默病的风险是否增加的试剂盒。还提供了用于确定受试者是否对活性制剂治疗相关疾病有反应的试剂盒。
• Disease risk factors and methods of use
  申请人：Zinfandel Pharmaceuticals, Inc.

  公开号：US11021751B2

  公开（公告）日：2021-06-01

  Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.

  本文提供了与相关疾病（如阿尔茨海默病）发展相关的基因变异。还提供了在检测到本文所述基因变异体时使用活性制剂（如使用特定活性制剂和/或在较早年龄使用）进行治疗的方法。在某些实施方案中，基因变异是 TOMM40 基因的缺失/插入多态性 (DIP)。